c raf kinase inhibitor pipeline insight

DelveInsight’s, “C-Raf Kinase Inhibitor– Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in C-Raf Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

C-Raf Kinase Inhibitor Understanding

C-Raf Kinase Inhibitor: Overview

The Raf proteins are central components of the mitogen-activated protein kinase (MAPK) pathway that regulates cell proliferation. The core pathway, first elucidated in the early 1990s, is now appreciated as one of the most common sources of oncogenic lesions in cancer. Overexpression or mutation of members of the epidermal growth factor (EGFR) protein family is a driving factor for numerous cancers, including pancreatic, lung (adenocarcinoma and non-small cell lung cancer (NSCLC)), head and neck squamous cell cancer, colorectal, glioblastoma, and (for EGFR2/HER2/NEU/ERBB2) breast cancer. In considering the relationship of Raf to the EGFR > Ras > Raf > MEK > ERK signaling cascades, there are a number of alternative methods by which Raf activity can be targeted. 1) An antisense or short hairpin RNA (shRNA) approach can be used to knockdown the Raf mRNA, depressing the steady state level of the protein. 2) Raf levels can also be depressed by selectively reducing Raf transcription, or by destabilizing Raf at the protein level. 3) The kinase activity of Raf can be directly targeted with a catalytic inhibitor. 4) The interaction of Raf with essential partner proteins such as its activator (Ras) or its effector (MEK) can be inhibited.

 

The role of the Raf-MAPK pathway in differentiation was originally examined in PC12 cells and showed a role both in cell differentiation and cell proliferation; a distinction that depended on MAPK activation levels versus its duration. However, in other cell lines, for example erythroblasts, C-Raf delays differentiation by inhibiting caspase activation. In epidermal development, C-Raf activation can induce terminal differentiation of keratinocytes. However, the specific role of C-Raf in this process is not clear since epidermis-specific C-Raf knockout does not affect epidermis architecture or follicle development. Also, two potential C-Raf activating phosphorylation sites, T491 and S494 have homologues in lin-45 and their substitution with aspartic acids results in a multi-vulval phenotype, indicating activation of the MAPK pathway.

 

Though C-Raf was the first Raf isoform identified as a potential cellular oncogene, the evidence to support its role as a prime oncogene, driving transformation, has not been forthcoming. This is apparent from the lack of identified activating C-Raf mutations or its aberrant expression in cancer. B-Raf, on the other hand, has been established in the past 3–5 years as a de facto oncogene and activating mutations in the gene are highly prevalent in several human cancers. Thus, agents targeting the Raf family as a whole or C-Raf exclusively have been extensively examined in many pre-clinical studies and more recently also in clinical trials.

 

The only naturally occurring transforming form of C-Raf described so far is a viral-transmitted form that has a deletion at the N-terminal regulatory region, resulting in a constitutively active kinase. This form can transform NIH 3T3 and other cell lines in culture, resulting in various cancerous phenotypes and the ability to form tumors in nude mice. It also induces tumor formation when expressed in transgenic animals. Other mutations, including point mutations that result in a constitutive kinase also display transforming activity in cell culture models, however, to date, these mutations have not been identified in primary cancer. Thus, C-Raf has not been considered as a de facto cellular oncogene.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence C-Raf Kinase Inhibitor R&D.
• In April 2019, Apollomics announced positive data for the Company’s multi-kinase inhibitor, APL-102, as both a single agent and in combination with an anti-PD-1 antibody in multiple preclinical studies.

C-Raf Kinase Inhibitor Emerging Drugs Chapters

This segment of the C-Raf Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

C-Raf Kinase Inhibitor Emerging Drugs

 

Sorafenib/MG 010 - Metagone Biotech

MG010 is a newly synthesized compound developed by Metagone. It is a C-Raf inhibitor, which demonstrates inhibition effect on mitochondrial C-Raf and the phosphorylated Death-Associated Protein Kinase (DAPK) complex in cancer cell together with another C-Raf inhibitor-Sorafenib. This MG-D-1609 causes mitochondria dysfunction, therefore, cut off energy supply and leading to cancer cell death. The MG-D-1609 can accurately identify and kill specific cancer cells, lower down the possibility of side effects and drug resistance. The in vitro and in vivo results have showed the great efficacy of 1609 in lung, colorectal, kidney and liver cancer cell lines. Since the urgent need have this disease but lack of better options for patients suffered from above cancers. MG-D-1609 may be a breakthrough drug and expected to bring hope for patients with cancer patients. The MG-D-1609 is estimated to execute phase II clinical trial to prove the efficacy on lung, colorectal, liver and kidney cancer patients in Australia.

Further product details are provided in the report……..

C-Raf Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different C-Raf Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in C-Raf Kinase Inhibitor

There are approx. 10+ key companies which are developing the therapies for C-Raf Kinase Inhibitor. The companies which have their C-Raf Kinase Inhibitor drug candidates in the most advanced stage, i.e. phase II include, Metagone Biotech etc.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

C-Raf Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Intramuscular
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Small molecules
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

C-Raf Kinase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses C-Raf Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-Raf Kinase Inhibitor drugs.

C-Raf Kinase Inhibitor Report Insights

• C-Raf Kinase Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

C-Raf Kinase Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing C-Raf Kinase Inhibitor drugs?
• How many C-Raf Kinase Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage acting as C-Raf Kinase Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the C-Raf Kinase Inhibitor therapeutics?
• What are the clinical studies going on for C-Raf Kinase Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?